It was to the “deep frustration” of research director Mads Krogsgaard Thomsen that Novo Nordisk gave up on a year long project to develop an insulin pill, that would have given type 1 diabetics a needle-free alternative, in 2016.
The pill had been predicted to have a future as one of the world’s best-selling medicines, with potential sales of up to USD 10 billion a year, if Novo Nordisk could develop it to be market-ready.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.